EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Tor Steensrud
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steensrud, T.
Right arrow Articles by Sørlie, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steensrud, T.
Right arrow Articles by Sørlie, D. G.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Cardiac - physiology
Right arrow Myocardial protection

Eur J Cardiothorac Surg 2006;30:256-262
© 2006 Elsevier Science NL

Contractile recovery of heart muscle after hypothermic hypoxia is improved by nicorandil via mitochondrial KATP channels

Tor Steensruda,*, Øyvind Jakobsena, Kirsti Ytrehusb, Dag G. Sørliea

a Department of Cardiothoracic and Vascular Surgery, University Hospital North Norway, P.O. Box 102, N-9038 Tromsø, Norway
b Department of Medical Physiology, Faculty of Medicine, University of Tromsø, Norway

Received 28 December 2005; received in revised form 21 April 2006; accepted 26 April 2006.

* Corresponding author. Tel.: +47 776 26000; fax: +47 776 28298. (Email: tor.steensrud{at}unn.no).

Background: The ATP-sensitive potassium channel (KATP) opener nicorandil used instead of potassium in hypothermic cardioplegia significantly improves preservation of cardiac function and energetics in the in situ heart preparation. The present study, therefore, examines the effect of nicorandil at different temperatures and the role of sarcolemmal and mitochondrial KATP channels under ex vivo conditions using contractile force (CF) and action potential duration (APD) as end points. Methods: Guinea-pig papillary muscles at 37, 27, or 22 °C (1 Hz) were exposed to nicorandil 0.2–1.1 mM. The contributions of KATP channel subtypes in cardioprotection were examined using mitochondrial (mito) (0.1 mM) or non-selective (1.0 mM) concentrations of nicorandil, mito KATP blocker 5-hydroxyl decanoate (5HD, 300 µM) or sarcolemmal (sarc) KATP blocker HMR1098 (30 µM) before and during 140 min of hypothermic (22 °C) glucose-free hypoxia. Results: Nicorandil >0.5 mM shortened the APD, and this was abolished by hypothermia and HMR1098 but not by 5HD. Nicorandil in both tested concentrations preserved contractile force after hypoxia–reoxygenation significantly better than control (73.7 ± 4.4% and 75.8 ± 3.9% vs 40.6 ± 2.6%, n = 6 in each group). Protection was blocked by 5HD but not by HMR1098. 5HD and HMR1098 alone did not change recovery of contractile force compared to control. Conclusion: Shortening of APD and activation of sarc KATP by nicorandil were not related to myocardial protection. Thus, the mito KATP seems to play a significant role in cardioprotection compared to the sarc KATP also when substrate depletion and hypoxia are combined with hypothermia.

Key Words: Hypoxia • Hypothermia • Cardioplegia







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.